Details: pack, label wording, sources, registration
Actrapid 100 IU/ml, Solution
10 ml vial, solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation
7.6/10
Good
Details →
vetman assessment
Actrapid
×
100 IU/ml, 10 ml vial, solution for injection, human medicine
Assessed clinical scope Dog · Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation · IV,IM
Care setting Emergency/critical-care hospital with frequent bedside glucose, electrolyte and ECG monitoring
vetman score
7.6/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-035270 · Verified on 15 Oct 2026
Off-label use
A strong, well-characterised hospital option for canine DKA and selected life-threatening hyperkalaemia. Exact-product transparency and direct regular-insulin evidence are major strengths; off-label status and the need for intensive glucose, potassium and phosphorus surveillance keep it below the very-good band.
Regulatory and scientific credibility 8.5/10
The exact 100 IU/ml 10 ml Novo Nordisk vial has a transparent central EMA dossier and current Georgian and EU/GB human registrations. Soluble recombinant human insulin has direct veterinary protocol evidence, but Actrapid has no dog/cat authorisation and the assessed emergency indications remain off-label.
Clinical efficacy 8.0/10
Prospective and randomized canine studies show that titrated IV regular insulin reliably lowers glucose and resolves ketosis in most dogs; direct evidence also defines electrolyte needs and shows that fixed-rate infusion is usable but not clearly superior. Insulin plus dextrose is an established temporary potassium-shifting intervention, while definitive treatment must correct the cause.
Safety and tolerability 6.5/10
The dominant risks are predictable but potentially serious hypoglycaemia, hypokalaemia, hypophosphataemia and an excessively rapid glucose fall. With correct dilution, dextrose support and frequent reassessment they are usually manageable; dosing-equipment errors, delayed hypoglycaemia and use before restoring perfusion can cause major harm.
Clinical practicality 7.0/10
The ready 100 IU/ml solution is rapidly titratable by IV infusion or protocolled IM dosing and needs no reconstitution. It does require U-100 equipment, accurate bag or syringe preparation, allowance for container adsorption, IV access and repeated glucose/electrolyte checks; these are appropriate ICU burdens. A 1,000-IU vial may be wasteful when emergency use is infrequent.
Full-course cost-effectiveness -
Current comparable local treatment-course and hospital-use prices were not verified.
Important safety and use flags
This score covers acute monitored hospital use for DKA and selected life-threatening hyperkalaemia only. It does not rate chronic maintenance diabetes, routine home SC administration, every mild potassium elevation or any unmonitored protocol. The exact Actrapid vial is a human medicine and all assessed dog/cat uses are off-label. Record the product, U-100 concentration, route, protocol, infusion preparation and total delivered exposure; do not substitute another insulin formulation or concentration by name alone. Use only U-100 insulin syringes or a validated infusion system. U-40 equipment, decimal-place errors, confusing IU with ml or copying the amount added to a bag as a direct bolus can cause a potentially fatal overdose. Stabilise perfusion and start appropriate fluids before insulin in DKA unless the selected emergency protocol clearly requires otherwise. Confirm DKA with ketones and acid-base assessment, identify precipitating disease and do not treat hyperglycaemia alone as DKA. For DKA, measure glucose at least every 1–2 hours during aggressive treatment and avoid a fall faster than the selected protocol target. Measure potassium and phosphorus repeatedly, supplement when indicated, follow ketones and acid-base status, and add dextrose while continuing insulin when glucose reaches the protocol threshold. For hyperkalaemia, insulin shifts potassium temporarily and must be paired with dextrose unless a documented exceptional circumstance dictates otherwise. Recheck glucose and potassium for delayed hypoglycaemia or rebound, protect the myocardium with calcium when indicated, and remove potassium by treating the cause. Hypoadrenocorticism may present with baseline hypoglycaemia and often improves with fluids and glucocorticoids. Reserve insulin for selected severe persistent hyperkalaemia, give dextrose and check glucose every 30–60 minutes; never let potassium shifting delay definitive crisis treatment. Prepare IV dilution aseptically and account for adsorption to tubing or the infusion container. Prime according to the local validated protocol, label the final IU/ml prominently, use a dedicated line where feasible and independently double-check calculations, pump settings and patient weight. Do not use a cloudy, coloured, frozen, overheated or otherwise damaged solution. Store unopened vials at 2–8 C, protect from light, do not freeze, and follow the exact label after opening; the human product information permits six weeks below 25 C in use. Review concurrent glucocorticoids, progestogens, dextrose, beta-agonists, diuretics and other agents that alter glucose or potassium. Dose changes must follow bedside measurements rather than a fixed schedule; hypersensitivity to human insulin or an excipient is a contraindication. Assessment sources +
Close
Cat
Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation
7.4/10
Good
Details →
vetman assessment
Actrapid
×
100 IU/ml, 10 ml vial, solution for injection, human medicine
Assessed clinical scope Cat · Acute monitored hospital use of soluble human insulin for diabetic ketoacidosis and selected life-threatening hyperkalaemia; not chronic maintenance diabetes or routine treatment of mild potassium elevation · IV,IM
Care setting Emergency/critical-care hospital with frequent bedside glucose, electrolyte and ECG monitoring
vetman score
7.4/10
Good
Evidence confidence: Medium
Georgia: Yes, human · № რ-035270 · Verified on 15 Oct 2026
Off-label use
A clinically useful hospital option for feline DKA and selected life-threatening hyperkalaemia. Exact-product transparency and direct feline regular-insulin evidence support a good score, while smaller heterogeneous studies and intensive biochemical monitoring keep confidence and efficacy below the canine assessment.
Regulatory and scientific credibility 8.5/10
The exact 100 IU/ml 10 ml Novo Nordisk vial has a transparent central EMA dossier and current Georgian and EU/GB human registrations. Soluble recombinant human insulin has direct veterinary protocol evidence, but Actrapid has no dog/cat authorisation and the assessed emergency indications remain off-label.
Clinical efficacy 7.5/10
Feline evidence directly supports IV CRI and intermittent IM regular-insulin protocols, but studies are small and heterogeneous, recent ketosis resolution was less consistent than in dogs, and no regimen is uniformly superior. Insulin plus dextrose is an established temporary potassium-shifting intervention, not definitive potassium removal.
Safety and tolerability 6.5/10
The dominant risks are predictable but potentially serious hypoglycaemia, hypokalaemia, hypophosphataemia and an excessively rapid glucose fall. With correct dilution, dextrose support and frequent reassessment they are usually manageable; dosing-equipment errors, delayed hypoglycaemia and use before restoring perfusion can cause major harm.
Clinical practicality 7.0/10
The ready 100 IU/ml solution is rapidly titratable by IV infusion or protocolled IM dosing and needs no reconstitution. It does require U-100 equipment, accurate bag or syringe preparation, allowance for container adsorption, IV access and repeated glucose/electrolyte checks; these are appropriate ICU burdens. A 1,000-IU vial may be wasteful when emergency use is infrequent.
Full-course cost-effectiveness -
Current comparable local treatment-course and hospital-use prices were not verified.
Important safety and use flags
This score covers acute monitored hospital use for DKA and selected life-threatening hyperkalaemia only. It does not rate chronic maintenance diabetes, routine home SC administration, every mild potassium elevation or any unmonitored protocol. The exact Actrapid vial is a human medicine and all assessed dog/cat uses are off-label. Record the product, U-100 concentration, route, protocol, infusion preparation and total delivered exposure; do not substitute another insulin formulation or concentration by name alone. Use only U-100 insulin syringes or a validated infusion system. U-40 equipment, decimal-place errors, confusing IU with ml or copying the amount added to a bag as a direct bolus can cause a potentially fatal overdose. Stabilise perfusion and start appropriate fluids before insulin in DKA unless the selected emergency protocol clearly requires otherwise. Confirm DKA with ketones and acid-base assessment, identify precipitating disease and do not treat hyperglycaemia alone as DKA. For DKA, measure glucose at least every 1–2 hours during aggressive treatment and avoid a fall faster than the selected protocol target. Measure potassium and phosphorus repeatedly, supplement when indicated, follow ketones and acid-base status, and add dextrose while continuing insulin when glucose reaches the protocol threshold. For hyperkalaemia, insulin shifts potassium temporarily and must be paired with dextrose unless a documented exceptional circumstance dictates otherwise. Recheck glucose and potassium for delayed hypoglycaemia or rebound, protect the myocardium with calcium when indicated, and remove potassium by treating the cause. Hypoadrenocorticism may present with baseline hypoglycaemia and often improves with fluids and glucocorticoids. Reserve insulin for selected severe persistent hyperkalaemia, give dextrose and check glucose every 30–60 minutes; never let potassium shifting delay definitive crisis treatment. Prepare IV dilution aseptically and account for adsorption to tubing or the infusion container. Prime according to the local validated protocol, label the final IU/ml prominently, use a dedicated line where feasible and independently double-check calculations, pump settings and patient weight. Do not use a cloudy, coloured, frozen, overheated or otherwise damaged solution. Store unopened vials at 2–8 C, protect from light, do not freeze, and follow the exact label after opening; the human product information permits six weeks below 25 C in use. Review concurrent glucocorticoids, progestogens, dextrose, beta-agonists, diuretics and other agents that alter glucose or potassium. Dose changes must follow bedside measurements rather than a fixed schedule; hypersensitivity to human insulin or an excipient is a contraindication. Assessment sources +
Close
Administration route
Subcutaneous, Intramuscular, Intravenous
Registration
Georgia
Yes, human
In force until 20 May 2027
Human (Ministry of Health, RAMA)
№ რ-035270
Verified on: 15 Oct 2026
EU
Yes, human
UK
Yes, human
№ PLGB046680354
Verified on: 16 Oct 2026
US
No
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
